Biased signaling of the angiotensin II type 1 receptor can be mediated through distinct mechanisms

Marie Mi Bonde1, Jonas Tind Hansen, Samra Joke Sanni

  • 1Laboratory for Molecular Cardiology, The Danish National Research Foundation Centre for Cardiac Arrhythmia, The Heart Centre, Copenhagen University Hospital, Rigshospitalet, and The Danish National Research Foundation Centre for Cardiac Arrhythmia, Faculty of Health Sciences, University of Copenhagen, Copenhagen, Denmark.

Plos One
|December 15, 2010
PubMed
Abstract

Insights

Investigating Angiotensin II type 1 receptor (AT1R) mutants reveals distinct mechanisms for G protein uncoupling. Some mutants enhance β-arrestin recruitment, while others impair it, impacting drug discovery for seven transmembrane receptors (7TMRs).

Area of Science:

  • Pharmacology
  • Molecular Biology
  • Biochemistry

Background:

  • Seven transmembrane receptors (7TMRs) can selectively activate G protein or β-arrestin pathways.
  • Pathway separation in receptors like the Angiotensin II type 1 receptor (AT1R) offers therapeutic opportunities.
  • Understanding the molecular basis of selective G protein uncoupling is crucial.

Purpose of the Study:

  • To investigate the mechanisms underlying pathway separation in AT1R mutants.
  • To differentiate between G protein uncoupling caused by impaired G protein interaction versus enhanced β-arrestin recruitment.
  • To explore the implications for drug discovery and 7TMR biology.

Main Methods:

  • Studied five AT1R mutants (D74N, DRY/AAY, Y292F, N298A, Y302F) known for pathway separation.
  • Assessed β-arrestin recruitment in response to specific ligands.

Main Results:

  • Mutants D74N, DRY/AAY, and N298A showed increased β-arrestin recruitment compared to wild-type (WT).
  • Mutants Y292F and Y302F exhibited impaired β-arrestin recruitment with a specific Ang II ligand (SII).

Conclusions:

  • AT1R mutant conformations induce distinct G protein uncoupling mechanisms.
  • Enhanced β-arrestin recruitment is a key mechanism for some mutants.
  • Findings highlight the need to elucidate molecular determinants for G protein and β-arrestin interactions in 7TMRs for drug development.

Related Concept Videos

Antihypertensive Drugs: Angiotensin II Receptor Blockers01:30

Antihypertensive Drugs: Angiotensin II Receptor Blockers

In the renin-angiotensin-aldosterone system, a hormone called angiotensin II plays a crucial role. It binds to the AT1 receptors in vascular smooth muscles coupled with Gq proteins. The activation of these receptors activates an enzyme called phospholipase C, which releases two molecules: inositol trisphosphate and diacylglycerol. These molecules cause a chain reaction that leads to the phosphorylation of myosin light chains and promotes interaction between actin and myosin, leading to smooth...
Antihypertensive Drugs: Direct Renin Inhibitors01:25

Antihypertensive Drugs: Direct Renin Inhibitors

The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
Interactions Between Signaling Pathways01:19

Interactions Between Signaling Pathways

Signaling cascades usually lack linearity. Multiple pathways interact and regulate one another, allowing cells to integrate and respond to diverse environmental stimuli.
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors01:30

Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors

Angiotensin-converting enzyme (ACE), a vital component of the renin-angiotensin-aldosterone system, is abundant in lung endothelial cells. ACE converts the inactive decapeptide, angiotensin I, into the active octapeptide, angiotensin II. This potent vasoconstrictor narrows blood vessels, increasing resistance to blood flow and elevating blood pressure. Angiotensin II also stimulates aldosterone production, encouraging kidney cells to reabsorb more sodium and water from urine, thereby increasing...
Adrenergic Receptors: ɑ Subtype01:31

Adrenergic Receptors: ɑ Subtype

Adrenoceptors are classified into α and ꞵ classes based on their potencies to catecholamine agonists. α-adrenoceptors show the following order of catecholamine potency:
Adrenaline ≥ Noradrenaline >> Isoprenaline
α-adrenoceptors are further divided into α1 and α2-adrenoceptors.
α1-Adrenoceptors: These receptors are located postsynaptically on the effector organs and cause constriction of smooth muscle mediated by activation of phospholipase C—inositol-1,4,5-trisphosphate...
Amplifying Signals via Enzymatic Cascade01:22

Amplifying Signals via Enzymatic Cascade

When a ligand binds to a cell-surface receptor, the receptor's intracellular domain changes shape, which may either activate its enzyme function or allow its binding to other molecules. The initial signal is amplified by most signal transduction pathways. This means that a single ligand molecule can activate multiple molecules of a downstream target. Proteins that relay a signal are most commonly phosphorylated at one or more sites, activating or inactivating the protein. Kinases catalyze the...